Latest total liabilities for KMPH: $73M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Zevra Therapeutics (KMPH) currently reports a total liabilities of $73M as of March 2026. That compares with $130M in the prior-year period — down 44.7% year over year. Use the charts on this page to explore Zevra Therapeutics's total liabilities history and peer comparisons.
Zevra Therapeutics's total liabilities decreased from $130M to $73M — a 44.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Zevra Therapeutics reported $73M in total liabilities as of March 2026. That compares with $130M in the prior-year period — down 44.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total liabilities of $73M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Zevra Therapeutics, and consider following KMPH for alerts when major investors trade the stock.
Zevra Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $73M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KMPH with unrelated industries.